Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
Portfolio Pulse from
VolitionRx Limited announced that its Nu.Q® Lung Cancer Test successfully differentiated between malignant and benign nodules in a large-scale study, enhancing the diagnostic process for lung cancer patients.
December 10, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VolitionRx Limited's Nu.Q® Lung Cancer Test demonstrated effectiveness in distinguishing between malignant and benign nodules in a study, potentially boosting its market position and stock value.
The successful differentiation of nodules by the Nu.Q® Test in a large-scale study suggests a significant advancement in lung cancer diagnostics. This could lead to increased adoption of the test, enhancing VolitionRx's market position and potentially driving up its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100